share_log

福安药业(300194.SZ):子公司撤回乙酰半胱氨酸注射液的药品注册申请

Fuan Pharmaceutical (300194.SZ): A subsidiary has withdrawn the pharmaceutical registration application for acetylcysteine injection.

Gelonghui Finance ·  Dec 23, 2024 08:54

On December 23, Gelonghui reported that Fuan Pharmaceutical (300194.SZ) announced that its wholly-owned subsidiary, Fuan Pharmaceutical Group Qingyutang Pharmaceutical Co., Ltd. (hereinafter referred to as "Qingyutang"), recently received the "Drug Registration Application Termination Notice" issued by the National Medical Products Administration.

The indication for acetylcysteine injection is for the treatment of acetaminophen overdose. Due to market changes and other factors and after careful study, in combination with the company's research and development strategy, the company has decided to actively withdraw this registration application.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment